Identification of lymphocyte cell-specific protein-tyrosine kinase (LCK) as a driver for invasion and migration of oral cancer by tumor heterogeneity exploitation

• Published in: Molecular cancer Vol. 20; no. 1; pp. 88 - 23
• Main Authors: Weiße, Jonas, Rosemann, Julia, Müller, Lisa, Kappler, Matthias, Eckert, Alexander W., Glaß, Markus, Misiak, Danny, Hüttelmaier, Stefan, Ballhausen, Wolfgang G., Hatzfeld, Mechthild, Haemmerle, Monika, Gutschner, Tony
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11.06.2021; BioMed Central; BMC
• Subjects: Adherens junctions; Analysis; Antineoplastic Agents - pharmacology; Carcinoma, Squamous Cell - genetics; Carcinoma, Squamous Cell - pathology; Cell culture; Cell differentiation; Cell Line, Tumor; Cell Movement - drug effects; Cell Movement - genetics; Clonal heterogeneity; Dasatinib; Dasatinib - pharmacology; EMT; Gene expression; Health aspects; HNSCC; Humans; Invasion; Invasiveness; ITH; Kinases; Lck protein; Lethality; Leukocyte migration; Lymphocyte Specific Protein Tyrosine Kinase p56(lck) - genetics; Lymphocytes; Metastases; Metastasis; Motility; Mouth cancer; Mouth Neoplasms - genetics; Mouth Neoplasms - pathology; Neoplasm Invasiveness - genetics; Neoplasm Invasiveness - pathology; Oral cancer; Phenols; Protein-tyrosine kinase; Proteins; RNA; Scientific equipment and supplies industry; Therapeutic targets; Tongue; Transcriptome; Transcriptomes; Tumor cell lines; Tumors; Tyrosine; United States; New York; United States > US; Dasatinib; OSCC; Src; HNSCC; Clonal heterogeneity; Metastasis; ITH; EMT; Invasion

Cancer metastases are the main cause of lethality. The five-year survival rate for patients diagnosed with advanced stage oral cancer is 30%. Hence, the identification of novel therapeutic targets is an urgent need. However, tumors are comprised of a heterogeneous collection of cells with distinct g...